.
Technical consultation to support the transition to the WHO 2019 guidelines on DR-TB treatment
WHO
Drug-resistant tuberculosis (DR-TB) is a key driver of the TB epidemic in the WHO European Region and one of the reasons that TB remains a major public health threat. Recent improvements in treatment success in the Region are encouraging, but probably insufficient to eliminate TB by 2030 and reach the End TB and Sustainable Development Goal targets. Without further improvements, the majority of new TB patients could be suffering from drug-resistant forms of the disease in a generation’s time.
Further reading: Technical consultation to support the transition to the WHO 2019 guidelines on DR-TB treatment
WHO consolidated guidelines on drug-resistant tuberculosis treatment
